138 related articles for article (PubMed ID: 36549768)
1. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S
Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F
Breast Cancer; 2022 Jan; 29(1):131-143. PubMed ID: 34491513
[TBL] [Abstract][Full Text] [Related]
4. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
5. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
6. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Tsurutani J; Hara F; Kitada M; Takahashi M; Kikawa Y; Kato H; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Taira N; Takashima T; Kashiwabara K; Aihara T; Mukai H
Breast; 2021 Feb; 55():63-68. PubMed ID: 33341707
[TBL] [Abstract][Full Text] [Related]
8. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial.
Lustberg M; Wu X; Fernández-Martínez JL; de Andrés-Galiana EJ; Philips S; Leibowitz J; Schneider B; Sonis S
Support Care Cancer; 2023 Jan; 31(2):139. PubMed ID: 36707490
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
Brady BL; Lucci M; Wilson K; Fox KM; Wojtynek J; Cooper C; Varker H; Chebili CL; Dokubo I
Am J Manag Care; 2021 Jan; 27(1 Spec. No.):SP37-SP43. PubMed ID: 33395243
[TBL] [Abstract][Full Text] [Related]
11. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Mehrotra S; Sharma MR; Gray E; Wu K; Barry WT; Hudis C; Winer EP; Lyss AP; Toppmeyer DL; Moreno-Aspitia A; Lad TE; Valasco M; Overmoyer B; Rugo H; Ratain MJ; Gobburu JV
AAPS J; 2017 Sep; 19(5):1411-1423. PubMed ID: 28620884
[TBL] [Abstract][Full Text] [Related]
12. Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer.
Ohno T; Mine T; Yoshioka H; Kosaka M; Matsuda S; De Kerckhove M; De Kerckhove C; Irie J; Inoue K; Haraguchi M; Kitajima M; Shinichiro I; Tokai H; Tanaka T; Izumida R
Anticancer Res; 2014 Aug; 34(8):4213-6. PubMed ID: 25075049
[TBL] [Abstract][Full Text] [Related]
13. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM
Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
[TBL] [Abstract][Full Text] [Related]
16. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
[TBL] [Abstract][Full Text] [Related]
18. Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial.
Kanbayashi Y; Sakaguchi K; Ishikawa T; Tabuchi Y; Takagi R; Yokota I; Katoh N; Takayama K; Taguchi T
Med Oncol; 2022 Jul; 39(10):153. PubMed ID: 35852641
[TBL] [Abstract][Full Text] [Related]
19. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
[TBL] [Abstract][Full Text] [Related]
20. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
